Ibrutinib is used in the treatment of mantle-cell lymphoma and blood cancer (chronic lymphocytic leukemia). It is also used in chronic lymphocytic leukaemia who have received at least one prior therapy or with 17p deletion.

Ibrutinib is a Bruton’s tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Headache, Fever, Diarrhea, Stomatitis (Inflammation of the mouth), Nausea, Low blood platelets, Decreased white blood cell count (neutrophils), Fatigue, Musculoskeletal (bone, muscle or joint) pain, Rash, Anemia (low number of red blood cells), Bruising, Muscle spasm, Hemorrhage, Pneumonia, Cough, Dry eye, High blood pressure, Weight loss, Urinary tract infection, Peripheral edema, Subdural hematoma, Second primary malignancies